Skip to content
thestock.space

As of 6 Nov 2026, Tarsons Products trades at 151.7× trailing earnings, above the industry P/E of 28.6×, and the shares are 15% below their 52-week high. Its ROCE of 4.8% is the lowest among the 7 largest Medical Instruments & Supplies peers, and sales grew 14% a year over 3 years while net profit fell 44%. Debt is 0.62× equity. It is a small-cap company with a market cap of ₹1,686 Cr, ranked 4th of 11 Medical Instruments & Supplies companies by market cap; the shares rose 11% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹314.00
Day high
₹320.95
Day low
₹312.65
Prev. close
₹318.40
Volume
26.7K

Health check

1 good · 1 fair · 4 to check
  • ReturnsAhead

    +10.9% over a year, better than 5 of 7 peers.

  • Price tagPricier

    P/E 151.7 vs industry 28.6.

  • GrowthSlow

    Sales +14.3%, profit −43.8% a year over 3 years.

  • ProfitabilityWeak

    ROCE 4.8% vs peer median 13.3%.

  • Balance sheetFair

    Debt 0.62× equity, interest covered 2.0×, Piotroski 5 of 9.

  • Red flags3 to check

    Return on equity is low at 2.3%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Instruments & Supplies

10 listed peers. Screen the industry

Small cap

₹1,686 Cr, #4 of 11 in its industry by size.

Defensive

Beta 0.33 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹441 Cr · profit ₹11 Cr
Market cap
₹1,686 Cr
Small cap
P/E
151.7
Industry 28.6
Price to book
2.64
Peers 5.26
Dividend yield
0.00%
ROE
2.3%
Peers 11.0%
ROCE
4.8%
Peers 13.3%
Debt to equity
0.62
Debt ₹393 Cr
EPS (TTM)
₹2.09
Face value ₹2
OPM (TTM)
27.0%
Net margin 2.5%
Sales growth
+20.7%
Latest quarter vs a year ago
Profit growth
−181.0%
Latest quarter vs a year ago
Price to sales
3.82
EV/EBITDA 16.9

Strengths and risks

Strengths

  • Quarterly sales up 20.7% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 2.3%.
  • Quarterly profit down 181.0% on a year ago.
  • P/E of 151.7 against an industry P/E of 28.6.

Derived automatically from reported figures. Not a recommendation.

About Tarsons Products

Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers assay plates, biohazard and safetyware, bioprocessing solutions, bottles and carboys, boxes and racks, cell culture ware, centrifuge ware, clamps and stands, clinical and microbiology products, cryoware, desiccators, tubings and connectors, filtration products, general labware, genomics and PCR consumables, laboratory…

Headquarters
Kolkata
Employees
1,108
Sector
Healthcare
ISIN
INE144Z01023
Website
tarsons.com

Price range

52 weeks

₹164.45₹375.00

Today

₹312.65₹320.95
Avg volume (3M)
4.5 L
1-year return
plus 10.9%
From 52-week high
minus 15.5%

Peers · Medical Instruments & Supplies

Compare with peersScreen the whole industry
Company
LENSKARTLenskart Solutions724.75plus 0.89%1,25,562160.713.487.2%6.7%20.8%––0.00%plus 79.8%
AGARWALEYEDr. Agarwal's Health Care516.35plus 0.91%16,37394.17.669.7%6.8%15.0%26.9%12.3%0.00%minus 0.7%
POLYMEDPoly Medicure1,612.30plus 0.63%16,34351.45.2613.3%11.0%15.2%18.8%21.6%0.22%minus 18.1%
TARSONSTarsons Products316.95minus 0.46%1,686151.72.644.8%2.3%−0.9%14.3%−43.8%0.00%plus 10.9%
LAXMIDENTLLaxmi Dental196.42minus 0.05%1,08134.84.4411.5%12.8%16.4%19.5%–0.00%minus 37.9%
PREVESTPrevest Denpro397.85minus 3.85%47822.03.8321.9%17.8%34.8%12.4%9.3%0.25%minus 21.2%
QMSMEDIQMS Medical Allied Services168.66minus 0.69%32628.65.6818.4%10.5%12.0%18.4%16.7%0.30%plus 75.0%
SHREEPACShree Pacetronix170.00plus 0.32%6419.53.4125.0%19.7%24.8%2.2%−1.2%0.00%minus 38.5%
Median of 7 peers–0.32%1,08134.85.2613.3%11.0%16.4%18.6%12.3%0.00%−18.1%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
91.4102108121110
66.774.976.486.784.3
24.727.431.534.326
27.0%26.8%29.2%28.3%23.6%
3.35.88.46.66
5.15.266.36.3
19.922.52529.127
––−1.30.2–
35.67.55.8−1.3
41.2%40.6%32.9%27.5%−9.1%
1.83.354.2−1.4
0.340.620.950.79-0.27

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+14.3%
Profit CAGR 3Y
−43.8%
EPS CAGR 3Y
−43.8%
ROE
2.3%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
281295391421
–+4.8%+32.5%+7.7%
148191275292
133104116128
47.3%35.2%29.6%30.5%
8.37.610.414.7
4.41019.322.4
28.540.462.596.5
0.3−0.10.4−2.2
10960.844.821.9
25.8%29.8%33.6%34.6%
80.742.629.814.3
–minus 47.2%minus 30.2%minus 51.9%
15.178.015.602.69

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
10.610.610.610.6
559602620624
111269339393
45.790.3111158
7269721,0801,186
467659765848
243392293175
4.10.10.85.8
59.122.625.725.3
−46.9−102−4.9132
7269721,0801,186

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
75.6103114118
−179−285−145−130
84.613638.98.9
−18.4−46.67.7−3
−190−184−152−126
−114−81.6−37.5−7.1

Shareholding pattern

Source: NSE filings
47.3%
promoters
  • Promoters47.30%
  • Public52.70%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202647.30%52.70%0.00
30 Jun 202647.30%52.70%0.00
31 Mar 202647.30%52.70%0.00
31 Dec 202547.30%52.70%minus 0.01
30 Sep 202547.31%52.69%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you